Cite

HARVARD Citation

    Foley, J. et al. (2022). 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS. Journal of neurology, neurosurgery and psychiatry. 93 (9), pp. e2-. [Online]. 
  
Back to record